Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Treatments For Psoriasis, Ovarian Cancer And MS Seeking CHMP Thumbs Up This Week

Executive Summary

Fourteen medicines that are in the final stages of the evaluation process at the European Medicines Agency should find out this week whether they will be approved for marketing across the EU.

Advertisement

Related Content

Janssen's Sirukumab Faces Difficult US Commercial Path Even If It Clears Approval Hurdles
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
Pulled From EU Assessment Process: Orphan Drugs For Kidney Disease, Mesothelioma
Boehringer Aims To Block GSK's Triple COPD Inhaler, Citing Combo Rule
Genentech's Ocrevus Manufacturing Process Still A Work In Progress
Three CHMP Negative Opinions ‒ But Who Got A Boon?
AB Science Asks For Re-examination After EMA Rejects Masitinib For Mastocytosis
Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval
Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick
CHMP’s January Recommendations Include Tofacitinib And Biosimilar Adalimumab

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121521

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel